Crystal's MCW Coder Hub🧬 ICD-10-CM H35.051 - Retinal Neovascularization, Unspecified, Right Eye
📋 Code Identity
| Field | Detail |
|---|---|
| ICD-10-CM Code | H35.051 |
| Full Descriptor | Retinal Neovascularization, Unspecified, Right Eye |
| Abbreviation | Retinal NV / NVE - Right Eye |
| Code Type | ICD-10-CM Diagnosis (Billable) |
| Effective Date | FY 2026 (October 1, 2025 - September 30, 2026) |
| Chapter | 7 - Diseases of the Eye and Adnexa (H00-H59) |
| Block | H30-H36 - Disorders of Choroid and Retina |
| Parent Category | H35 - Other Retinal Disorders |
| Subcategory | H35.0 - Background Retinopathy and Retinal Vascular Changes |
| Sub-Subcategory | H35.05 - Retinal Neovascularization, Unspecified |
| Laterality | 6th character = 1 (Right Eye) |
| Billable? | ✅ Yes — 6 characters, fully specified |
| ”Code Also” Instruction | Code also any associated hypertension I10 |
| Chronic Condition | Yes |
| CC/MCC Status | Non-CC / Non-MCC |
| CMS FA Coverage | ✅ Listed in CMS Ophthalmic Angiography LCD Group 1 codes |
| CMS Posterior Segment OCT Coverage | ✅ Listed in CMS SCODI/Posterior Segment Imaging LCD |
⚠️ Laterality Reminder: H35.051 is right eye only. Use H35.052 for the left eye, H35.053 for bilateral involvement, and H35.059 for unspecified eye. The word “unspecified” in the descriptor refers to the etiology of neovascularization (i.e., non-diabetic cause not further specified), not the laterality, which is clearly right eye.
🔴 WHEN NOT TO USE THIS CODE: If the patient has any documented diabetes mellitus and retinal neovascularization is present, do not use H35.051. Use the appropriate proliferative diabetic retinopathy code from the E08-E13 family (e.g., E11.3519 for Type 2 DM with proliferative diabetic retinopathy without other diabetic retinopathy without macular edema, unspecified eye). The Excludes 2 at H35.0 applies here — when DM is the etiology, it belongs in the E-code family.
🔬 Clinical Description
Retinal neovascularization (NV) is the pathological growth of new, abnormal blood vessels within or on the surface of the retina, driven by chronic retinal ischemia and upregulation of pro-angiogenic factors — most prominently vascular endothelial growth factor (VEGF-A). Unlike the normal retinal vasculature, neovascular vessels are structurally immature: they lack tight junctions between endothelial cells, have no pericyte coverage, and are highly prone to leakage, hemorrhage, fibrosis, and traction. Left untreated, retinal neovascularization carries a high risk of vitreous hemorrhage (VH), tractional retinal detachment (TRD), and irreversible vision loss.
The H35.05x code family captures non-diabetic retinal neovascularization — neovascularization arising from ischemia caused by conditions other than diabetes mellitus. This is a critical distinction: when diabetes is the documented driver, the E08-E13 proliferative diabetic retinopathy code families take priority and H35.051 should not be used.
Pathophysiology
Regardless of the underlying etiology, the final common pathway of retinal NV involves:
- Retinal ischemia — Capillary occlusion, arterial occlusion, venous occlusion, or mechanical/radiation-induced vascular damage creates zones of oxygen-deprived retina (non-perfused retina, NPR).
- VEGF upregulation — Ischemic retinal cells (particularly Müller cells and retinal ganglion cells) dramatically upregulate VEGF-A production in response to hypoxia. VEGF diffuses through the vitreous and reaches the retinal vascular endothelium.
- Endothelial activation and sprouting — VEGF binds VEGFR-2 on retinal capillary endothelial cells, triggering proliferation, migration, and tube formation. New vessels bud from existing capillaries or venules at the margin of the ischemic zone.
- Neovascularization growth patterns:
- NVE (Neovascularization elsewhere) — NV arising from peripheral or mid-peripheral retinal vessels, often at the junction between perfused and non-perfused retina; grows toward the vitreous along the posterior hyaloid
- NVD (Neovascularization of the disc) — NV arising from or within one disc diameter of the optic nerve head; considered higher risk for vitreous hemorrhage and traction
- NVI/NVA (Neovascularization of the iris/angle) — Anterior segment NV; indicates severe pan-retinal ischemia; codes separately under anterior segment codes
- Fibrotic transformation — Over time, NV membranes undergo fibrosis, developing into fibrovascular proliferative membranes that can exert traction on the retina → TRD
Anatomic NV Classification
| NV Type | Location | Risk Level | Code Implications |
|---|---|---|---|
| NVE | Peripheral/mid-peripheral retina | Moderate — VH risk | H35.051 when non-diabetic |
| NVD | On or within 1 DD of optic disc | High — VH and TRD risk | H35.051 when non-diabetic; NVD is highest risk indicator for PRP urgency |
| NVI | Iris surface | High — neovascular glaucoma risk | Code with anterior segment NV codes; H40.841 for neovascular glaucoma |
| NVA | Anterior chamber angle | High — angle closure and glaucoma | See H40.8x family |
Non-Diabetic Causes of Retinal NV (H35.051 Etiology Spectrum)
| Etiology | Mechanism | Additional Codes |
|---|---|---|
| Branch Retinal Vein Occlusion (BRVO) | Venous stasis → ischemia → VEGF ↑ | H34.8311 (right eye BRVO) + H35.051 |
| Central Retinal Vein Occlusion (CRVO) | Pan-retinal venous stasis → diffuse ischemia → NVD/NVI | H34.8110 + H35.051 (or NVI code) |
| Branch Retinal Artery Occlusion (BRAO) | Arterial ischemia → inner retinal NV at ischemic margin | H34.231 + H35.051 |
| Sickle Cell Retinopathy (PSR) | Vaso-occlusion → peripheral ischemia → sea-fan NVE | D57.1 + H35.051; sea-fan is classic PSCR |
| Radiation Retinopathy | Radiation endothelial damage → capillary occlusion → ischemia | H59.311 (right eye) + H35.051 |
| Ocular Ischemic Syndrome (OIS) | Carotid stenosis → chronic hypoperfusion → NV | I65.21 + H35.051 |
| Coats Disease | Idiopathic retinal telangiectasia → exudation and ischemia | H35.021 + H35.051 when NV develops |
| Hypertensive Retinopathy | Severe ischemic hypertensive retinopathy → NV | H35.031 + I10 + H35.051 |
| Idiopathic/Other | No identifiable systemic etiology | H35.051 alone + I10 if hypertension present |
Imaging and Clinical Assessment
| Modality | Acute/Active NV Findings | Monitoring/Post-Treatment |
|---|---|---|
| Fundus Photography | Red/pink fronds of new vessels on retinal surface or disc; fibrovascular membranes | Regression of NV fronds post-PRP/anti-VEGF; fibrotic pale scar tissue |
| Fluorescein Angiography (FA) | Early hyperfluorescence of NV (vessels fill with dye rapidly); profuse late leakage from immature NV; delineates extent of capillary non-perfusion (NPR) | Post-PRP: reduced NV leakage; laser burn scars; persisting NPR |
| OCT Posterior Segment | Neovascular membrane on retinal surface or extending into vitreous; traction; posterior hyaloid elevation | Regression of NV membrane; inner retinal atrophy in ischemic zone |
| OCTA | Flow signal within NV fronds; capillary plexus dropout in NPR zone; delineates NV network morphology | Reduced NV flow signal post-treatment; persistent choriocapillaris flow voids |
| Wide-Field FA / Imaging | Essential for peripheral NV (PSCR, BRVO periphery); detects NV invisible on standard 30-55° imaging | Post-PRP peripheral burn mapping and NV regression assessment |
🔥 Treatment Urgency: NVD (neovascularization of the disc) in particular carries the highest risk of sudden, dense vitreous hemorrhage and requires urgent treatment. NVE involving the posterior pole approaches similar urgency. Wide-field imaging has dramatically improved detection of peripheral NV that would previously be missed on standard exam.
🌳 Code Tree
H35 - Other Retinal Disorders
│
├── H35.0 - Background Retinopathy and Retinal Vascular Changes
│ │
│ ├── H35.00 - Unspecified background retinopathy (billable)
│ │
│ ├── H35.01 - Changes in Retinal Vascular Appearance
│ │ ├── H35.011 - Right eye
│ │ ├── H35.012 - Left eye
│ │ ├── H35.013 - Bilateral
│ │ └── H35.019 - Unspecified eye
│ │
│ ├── H35.02 - Exudative Retinopathy (Coats Disease)
│ │ ├── H35.021 - Right eye
│ │ ├── H35.022 - Left eye
│ │ ├── H35.023 - Bilateral
│ │ └── H35.029 - Unspecified eye
│ │
│ ├── H35.03 - Hypertensive Retinopathy
│ │ ├── H35.031 - Right eye
│ │ ├── H35.032 - Left eye
│ │ ├── H35.033 - Bilateral
│ │ └── H35.039 - Unspecified eye
│ │
│ ├── H35.04 - Retinal Microaneurysms, Unspecified
│ │ ├── H35.041 - Right eye
│ │ ├── H35.042 - Left eye
│ │ ├── H35.043 - Bilateral
│ │ └── H35.049 - Unspecified eye
│ │
│ ├── H35.05 - Retinal Neovascularization, Unspecified
│ │ ├── H35.051 - Right eye ◀ THIS CODE
│ │ ├── H35.052 - Left eye
│ │ ├── H35.053 - Bilateral
│ │ └── H35.059 - Unspecified eye
│ │
│ ├── H35.06 - Retinal Vasculitis
│ │ ├── H35.061 - Right eye
│ │ ├── H35.062 - Left eye
│ │ ├── H35.063 - Bilateral
│ │ └── H35.069 - Unspecified eye
│ │
│ ├── H35.07 - Retinal Telangiectasis
│ │ ├── H35.071 - Right eye
│ │ ├── H35.072 - Left eye
│ │ ├── H35.073 - Bilateral
│ │ └── H35.079 - Unspecified eye
│ │
│ └── H35.09 - Other Intraretinal Microvascular Abnormalities
│ *(IRMA, retinal varices, other NOS microvascular changes)*
│
├── H35.2 - Other Non-Diabetic Proliferative Retinopathy
│ ├── H35.20 - Unspecified eye (billable)
│ ├── H35.21 - Right eye
│ ├── H35.22 - Left eye
│ └── H35.23 - Bilateral
│ *(Use H35.2x when NV has progressed to full proliferative retinopathy
│ with fibrovascular membranes — more advanced than H35.051)*
│
├── H35.3 - Degeneration of Macula and Posterior Pole
│ ├── H35.31 - Nonexudative AMD (Dry AMD)
│ └── H35.32 - Exudative AMD (Wet AMD/CNV)
│
└── H35.6 - Retinal Hemorrhage
├── H35.61 - Retinal hemorrhage, right eye
├── H35.62 - Retinal hemorrhage, left eye
└── H35.63 - Retinal hemorrhage, bilateral
🔍 H35.051 vs. H35.21 — Critical Distinction:
- H35.051 (Retinal NV, unspecified, right eye) — captures early to active neovascularization arising from the retina, non-diabetic etiology, without necessarily the degree of fibrovascular proliferative membrane formation
- H35.21 (Other non-diabetic proliferative retinopathy, right eye) — captures more advanced proliferative disease with fibrovascular proliferative membranes, traction, and significant progression beyond simple NV fronds
- When to use which: If the provider documents “retinal neovascularization” as a finding → H35.051. If the provider documents “non-diabetic proliferative retinopathy” with membranes and traction → H35.21. When in doubt, query the provider on the extent of proliferative disease.
✅ Includes
H35.051 captures the following in the right eye:
- Retinal neovascularization (NV) of non-diabetic etiology in the right eye — new vessel fronds on the retinal surface (NVE) or disc (NVD) arising from ischemic non-perfused retina
- Sea-fan neovascularization in the context of sickle cell retinopathy, right eye (classic proliferative sickle cell retinopathy finding)
- NV arising from BRVO or CRVO — venous occlusion-related retinal ischemia driving new vessel formation in the right eye
- NV secondary to radiation retinopathy — radiation-induced microvascular damage and ischemia
- NV in ocular ischemic syndrome — NV secondary to carotid stenosis and chronic retinal hypoperfusion
- Idiopathic retinal neovascularization when no systemic cause is identified
- NV secondary to Coats disease (0) when ischemia drives vessel proliferation
- Early fibrovascular activity at the NV frond interface, prior to development of full fibrovascular proliferative membrane
Code Also Instruction
📌 Mandatory: Code also any associated hypertension I10 when hypertension is documented in the medical record. This instruction applies to the entire H35.0 subcategory.
🚫 Excludes
Excludes 2 (These conditions can be coded together — they are not the same as H35.051)
| Excluded Code Range | Description | Guidance |
|---|---|---|
| E08.311-E08.359 | Diabetic retinal disorders - DM due to underlying condition | If DM due to underlying condition drives NV → use E08.35x proliferative codes, NOT H35.051 |
| E09.311-E09.359 | Diabetic retinal disorders - Drug/chemical-induced DM | Same — use E09.35x for PDR |
| E10.311-E10.359 | Diabetic retinal disorders - Type 1 DM | Use E10.35x for Type 1 PDR with NV |
| E11.311-E11.359 | Diabetic retinal disorders - Type 2 DM | Most common: Use E11.35x for Type 2 PDR — never H35.051 for diabetic NV |
| E13.311-E13.359 | Diabetic retinal disorders - Other specified DM | Use E13.35x for other DM types with PDR |
🔴 The Diabetic Boundary Rule (Critical):
- Patient has diabetes + retinal NV → ALWAYS use the appropriate E-code proliferative diabetic retinopathy code (E11.35xx series). H35.051 is wrong in this context.
- Patient has no diabetes + retinal NV (e.g., from BRVO, sickle cell, radiation, OIS) → H35.051 is correct.
- Patient has diabetes AND a separate non-diabetic cause of NV (e.g., bilateral BRVO + DM) → Complex scenario; query provider on documentation of attribution; in most cases the E-code family will drive the retinal NV coding with the BRVO coded as a secondary diagnosis.
🏥 HCC (Hierarchical Condition Category)
| Field | Detail |
|---|---|
| HCC Mapped? | ❌ No — H35.051 does not map to any CMS-HCC v28 category |
| RAF Score Contribution | None directly |
| Risk Adjustment Relevance | Low for the NV code itself |
💡 RAF Strategy — The Underlying Etiologies Are HCC-Rich: While H35.051 carries no HCC weight, the systemic conditions driving it often do. Ensure complete documentation and coding:
| Code | Description | HCC? | Notes |
|---|---|---|---|
| D57.1 | Sickle-cell disease without crisis | ✅ HCC 47 | PSR-related NV; significant RAF |
| D57.0 | Sickle-cell anemia with crisis | ✅ HCC 46 | Crisis state |
| I48.91 | Unspecified atrial fibrillation | ✅ HCC 96 | If A-fib contributes to RVO |
| I65.21 | Occlusion/stenosis, right carotid artery | ✅ HCC 108 | OIS-related NV |
| E11.9 | Type 2 DM without complications | ✅ HCC 19 | If DM present, switch to E11.35x for eye code |
| I10 | Essential hypertension | ❌ None | Mandatory code-also; no HCC |
| H34.8311 | BRVO right eye with macular edema | ❌ None | Underlying RVO cause |
| I25.10 | Atherosclerotic heart disease | ✅ HCC 88 | OIS/vascular disease context |
🏨 MS-DRG (Medicare Severity DRG)
| Field | Detail |
|---|---|
| CC/MCC Status | ⬜ Non-CC / Non-MCC |
| Primary MS-DRG (as PDx) | MS-DRG 124 - Other Disorders of the Eye with MCC |
| Primary MS-DRG (no CC/MCC) | MS-DRG 125 - Other Disorders of the Eye without MCC/CC |
| MDC | MDC 02 - Diseases and Disorders of the Eye |
| Inpatient Admission Likelihood | Low-Moderate — retinal NV is generally managed outpatient; inpatient admission may occur for complications (dense VH, TRD, acute vision loss) rather than NV alone |
🏥 Inpatient Note: H35.051 as a principal diagnosis driving inpatient admission is uncommon unless the NV has caused a complication (e.g., dense vitreous hemorrhage or tractional retinal detachment) requiring inpatient surgical intervention. In those scenarios, the complication (e.g., vitreous hemorrhage H43.13 or retinal detachment H33.041) is often the principal diagnosis, with H35.051 as a secondary etiology code. As a secondary diagnosis, H35.051 does not carry CC weight but contributes to clinical complexity documentation.
💊 Associated CPT Codes (Commonly Reported With H35.051)
wRVU values reflect 2025 CMS Medicare Physician Fee Schedule.
| CPT Code | Description | wRVU (Non-Fac) | wRVU (Facility) | Assistant Payable? | Relevance |
|---|---|---|---|---|---|
| 92235 | Fluorescein angiography with interpretation and report | 0.92 | 0.92 | No | Essential — confirms NV presence, leakage, extent of capillary non-perfusion; required for PRP medical necessity |
| 92134 | OCT posterior segment with interpretation and report | 0.00 | 0.00 | No | Documents NV membrane structure, traction, associated macular edema |
| 92137 | OCT with OCT angiography (OCTA) with interpretation and report (2025+) | 0.79 | 0.79 | No | Maps NV network flow; delineates NPR zones; cannot bill same day as 92134 |
| 92240 | ICG angiography with interpretation and report | 0.92 | 0.92 | No | Used in OIS or choroidal pathology context; supplements FA |
| 92242 | Combined FA + ICG angiography | 1.38 | 1.38 | No | Dual angiography when medically necessary |
| 92250 | Fundus photography with interpretation and report | 0.00 | 0.00 | No | Documents NV frond morphology, disc/retinal location; baseline for comparison |
| 67228 | Treatment of extensive or progressive retinopathy (e.g., PRP); photocoagulation, 1 or more sessions | 3.09 | 3.09 | No | Primary treatment for retinal NV — panretinal or scatter photocoagulation |
| 67227 | Destruction of localized lesion of retina; cryotherapy, one or more sessions | 3.43 | 3.43 | No | Cryotherapy for peripheral NV when laser delivery not possible (e.g., vitreous hemorrhage) |
| 67210 | Destruction of localized lesion of retina; photocoagulation | 3.43 | 3.43 | No | Focal laser for specific NV lesion/feeder vessel |
| 67028 | Intravitreal injection of a pharmacological agent | 0.72 | 0.72 | No | Anti-VEGF for NV — adjunct or alternative to PRP |
| 67108 | Repair of retinal detachment; vitrectomy, any method, with or without air/gas/laser (complex) | 17.77 | 17.77 | Yes | PPV for TRD or combined TRD/RRD complicating NV |
| 67113 | Repair of complex retinal detachment, with or without vitrectomy | 26.82 | 26.82 | Yes | Complex detachment repair |
| 99215 | E/M, established patient, high complexity | 2.85 | 2.85 | No | Active NV monitoring/treatment planning |
| 99205 | E/M, new patient, high complexity | 3.50 | 3.50 | No | New diagnosis of retinal NV |
| 99254 | Inpatient consult, moderate-high complexity | 5.30 | 5.30 | No | Consult for NV-related complication requiring inpatient management |
⚠️ Key CPT Billing Rules
- 67228 (PRP) — Per CMS LCD for Panretinal (Scatter) Laser Photocoagulation, H35.051 is an approved covered diagnosis. Documentation must include: NV extent, FA evidence of NPR, treatment session details, and response assessment
- 67028 (anti-VEGF) — Coverage for anti-VEGF in non-diabetic NV varies by payer. H35.051 is listed as a covered diagnosis in several MAC LCDs for intravitreal ranibizumab and aflibercept (off-label for non-diabetic NV in many cases); verify payer-specific LCD
- 92137 cannot be billed same day as 92134 — NCCI edit; choose one per DOS
- 67108 and 67113 are payable with assistant surgeon in appropriate settings — confirm payer policy and document medical necessity for assistant
- 92235 (FA) medical necessity for NV: CMS Ophthalmic Angiography LCD explicitly lists H35.051-H35.053 as covered indications for fluorescein angiography — this is a strong documentation support for FA claims with this diagnosis
🔧 Applicable Modifiers
| Modifier | Description | Application with H35.051 |
|---|---|---|
| -RT | Right side | Append to all laterality-specific CPT codes (imaging, laser, injection) for right eye |
| -LT | Left side | When fellow left eye also treated or imaged at the same encounter |
| -50 | Bilateral procedure | Bilateral imaging (FA, OCT) or bilateral PRP on the same day |
| -25 | Significant, separately identifiable E/M same day as procedure | Required when E/M + 67228 or 67028 on same date; E/M must be independently documented |
| -59 | Distinct procedural service | When two procedures are genuinely distinct; needed to bypass NCCI edits |
| -26 | Professional component | Physician interprets imaging performed technically at another facility |
| -TC | Technical component | Facility billing for technical imaging only |
| -54 | Surgical care only | When surgeon provides surgical care but not pre/post-op management |
| -55 | Postoperative management only | For the provider managing post-PPV/laser follow-up if different from operating surgeon |
| -57 | Decision for surgery | When E/M on same day as major surgery (e.g., PPV) is for the decision to perform the procedure — waives the global period for E/M |
| -GC | Service performed in part by resident | Teaching institution; attending must document supervision |
| -GA | ABN on file | Medicare beneficiary notified of potential non-coverage; ABN obtained |
| -AS | Assistant at surgery, non-physician | PA/NP assisting at 67108/67113 |
| -80 | Assistant surgeon (physician) | Physician assistant surgeon for 67108/67113 |
| -JW | Drug amount discarded | For anti-VEGF drug waste documentation |
| -JZ | Zero waste | Full vial used; no drug discarded |
📝 Coding Examples
Example 1 — BRVO with Retinal NV, Right Eye; PRP Performed
A 68-year-old established male with a known branch retinal vein occlusion (BRVO) of the right eye, treated with anti-VEGF 6 months ago for macular edema. Returns today. OCT shows resolved macular edema. However, on dilated exam, new retinal neovascularization (NVE) is noted along the inferior arcade peripherally — consistent with ischemia from the prior BRVO. FA is performed: confirms NVE with leakage and a large zone of peripheral capillary non-perfusion in the inferior quadrant, right eye. PRP laser photocoagulation is performed in the same session to the non-perfused zone.
Diagnosis Codes:
- H35.051 - Retinal neovascularization, unspecified, right eye (NVE from BRVO ischemia)
- H34.8312 - Tributary retinal vein occlusion, right eye, with retinal neovascularization (underlying BRVO — use most specific stage code; verify 7th character with documentation)
- I10 - Essential hypertension (mandatory code also)
CPT Codes:
- 99215 - -25 - E/M, established patient, high complexity
- 92235 - -RT - Fluorescein angiography, right eye (confirms NV and NPR extent)
- 67228 - -RT - PRP laser photocoagulation, right eye
💡 Coding Note: The BRVO code with retinal NV (H34.831x with 7th character “1”) and H35.051 can both be reported — the BRVO code captures the venous occlusion and its stage; H35.051 specifically flags the neovascularization finding for documentation and supports the medical necessity for PRP.
Example 2 — Proliferative Sickle Cell Retinopathy, Right Eye, Anti-VEGF + Laser
A 38-year-old female with sickle cell disease (Hb SC) presents for retina evaluation. Peripheral fundus exam confirms sea-fan neovascularization (NVE) superiorly in the right eye. Wide-field FA confirms peripheral NV with leakage and adjacent capillary non-perfusion. OCT-A maps the NV network and NPR zone. Intravitreal bevacizumab (off-label) is injected in the right eye as primary treatment, with plan to add targeted retinal photocoagulation at next visit if NV does not regress.
Diagnosis Codes:
- H35.051 - Retinal neovascularization, unspecified, right eye (sea-fan NVE — sickle cell-related)
- D57.1 - Sickle-cell disease without crisis (underlying systemic etiology; HCC 47)
- I10 - Only if hypertension is documented
CPT Codes:
- 99215 - -25 - E/M, established patient, high complexity
- 92235 - -RT - Fluorescein angiography, right eye (wide-field)
- 92137 - -RT - OCT with OCT angiography, right eye (cannot bill 92134 same day)
- 67028 - -RT - Intravitreal injection, right eye
HCPCS Drug Code:
- J9035 - Bevacizumab (Avastin), off-label for proliferative sickle cell retinopathy
- Modifier -JZ or -JW as applicable
- Modifier -GA if ABN obtained for off-label use
⚠️ Off-Label Anti-VEGF Alert: Bevacizumab for sickle cell NV is off-label for Medicare. Verify MAC LCD and consider ABN if Medicare patient. Some payers cover it under “proliferative retinopathy” indications — document medical necessity thoroughly.
Example 3 — Radiation Retinopathy with NV, Right Eye
A 62-year-old male with a history of proton beam radiation therapy for a choroidal melanoma (right eye, 4 years ago) presents with decreased vision, right eye. Exam reveals cotton-wool spots, microaneurysms, hard exudates, and new retinal neovascularization on the surface of the retina adjacent to the prior treated lesion site. FA confirms radiation-induced capillary non-perfusion with NV and leakage. OCT shows no macular edema currently.
Diagnosis Codes:
- H35.051 - Retinal neovascularization, unspecified, right eye
- H59.311 - Chorioretinal scars after surgery for detachment, right eye (use appropriate radiation retinopathy / post-procedural code — verify most current tabular guidance for radiation retinopathy; H35.09 or H59.x may also apply)
- H35.041 - Retinal microaneurysms, unspecified, right eye (if microaneurysms are separately documented as distinct finding)
- I10 - Essential hypertension (if documented)
CPT Codes:
- 99215 - -25 - E/M, established patient, high complexity
- 92235 - -RT - Fluorescein angiography, right eye
- 92134 - -RT - OCT posterior segment, right eye
📝 Radiation Retinopathy Coding Note: ICD-10-CM does not have a dedicated “radiation retinopathy” code in the H35.0 block. H35.051 is the most specific code for the NV finding. For the broader radiation-induced retinal changes, H35.09 (other intraretinal microvascular abnormalities) or an appropriate post-procedural/external cause code may be needed. Document clearly and query the provider on the complete clinical picture.
Example 4 — New Patient, Incidental NVD Found on Routine Exam, Urgent PRP
A 55-year-old male, new patient, referred urgently from optometry for new disc neovascularization right eye. Patient has no known diabetes. Medical history: hypertension, hyperlipidemia. Dilated exam: NVD visible on the right optic disc; no vitreous hemorrhage yet. FA confirms NVD with profuse leakage; extensive peripheral capillary non-perfusion. Urgent PRP is performed in the same visit.
Diagnosis Codes:
- H35.051 - Retinal neovascularization, unspecified, right eye (NVD — disc neovascularization)
- I10 - Essential hypertension (mandatory code also)
- E78.5 - Hyperlipidemia, unspecified
CPT Codes:
- 99205 - -57 - E/M, new patient, high complexity (decision for major surgery — PPV potentially planned; or use -25 if PRP is not a major procedure)
- 92235 - -RT - FA, right eye
- 67228 - -RT - PRP laser photocoagulation, right eye
💡 Modifier Note: For 67228 (PRP laser), the global period is 0 days for most CPT laser procedures — meaning -25 on the E/M is generally sufficient. Modifier -57 (decision for surgery) applies when the same-day E/M leads to a decision for a 90-day global surgical procedure. Verify the global period for 67228 in the CMS MPFS before choosing between -25 and -57.
Example 5 — NV with Vitreous Hemorrhage Complication, Inpatient PPV
A 70-year-old male with known right eye retinal neovascularization (BRVO-related) presents with sudden, complete vision loss in the right eye secondary to dense vitreous hemorrhage. OCT confirms pre-retinal hemorrhage and NV membrane. Patient is scheduled for urgent pars plana vitrectomy (PPV) with endolaser PRP.
Diagnosis Codes:
- H43.13 - Vitreous hemorrhage, right eye (principal — the acute complication driving admission/surgery)
- H35.051 - Retinal neovascularization, unspecified, right eye (underlying etiology)
- H34.8311 - Tributary retinal vein occlusion, right eye (underlying root cause)
- I10 - Essential hypertension
CPT Codes (Profee):
- 67108 - RT - Pars plana vitrectomy with endolaser PRP (see operative note for exact CPT; 67108 covers PPV with laser/gas/etc.)
- 99254 - 57 - Inpatient consult + decision for surgery (if on different day from surgery, -57 applies)
🏥 Inpatient Facility Coding: PDx H43.13 (vitreous hemorrhage) → MDC 02 → MS-DRG assignment; H35.051 as secondary diagnosis captures the NV etiology. Neither code is a CC but the OR procedure (67108) will drive DRG assignment to a surgical DRG.
🔗 Related Diagnoses to Consider Coding Together
| Code | Description | Relationship to H35.051 |
|---|---|---|
| I10 | Essential hypertension | Mandatory code also for entire H35.0 block |
| H35.052 | Retinal NV, unspecified, left eye | When bilateral — code each eye separately |
| H35.053 | Retinal NV, unspecified, bilateral | Use when both eyes affected at same level |
| H35.041 | Retinal microaneurysms, unspecified, right eye | Often coexists with NV in ischemic retinopathy |
| H35.031 | Hypertensive retinopathy, right eye | Hypertension-driven background changes alongside NV |
| H35.09 | Other intraretinal microvascular abnormalities | IRMA — may precede or coexist with NV |
| H35.21- | Other non-diabetic proliferative retinopathy, right eye | When NV has advanced to full fibrovascular proliferative retinopathy |
| H34.8311 | Tributary retinal vein occlusion, right eye, with NV | BRVO as etiology of NV |
| H34.8110 | Central retinal vein occlusion, right eye, with macular edema | CRVO as etiology of NV |
| H34.231 | Branch retinal artery occlusion, right eye | BRAO ischemia driving NV |
| H43.13 | Vitreous hemorrhage, right eye | Complication of ruptured NV frond |
| H33.041 | Traction retinal detachment with vitreoretinal organization, right eye | Advanced complication of fibrosed NV membranes |
| H40.841 | Neovascular secondary angle-closure glaucoma, right eye (new FY2026) | Anterior segment extension of posterior NV → NVI/NVA |
| D57.1 | Sickle-cell disease without crisis | PSCR-related NV; HCC 47 |
| D57.0 | Sickle-cell anemia with crisis | Active sickle crisis with retinal complications |
| E78.5 | Hyperlipidemia, unspecified | Common vascular risk factor |
| I65.21 | Occlusion and stenosis of right carotid artery | OIS etiology; HCC 108 |
⚖️ H35.051 vs. E11.35x — Decision Guide
The most important distinction in retinal NV coding.
| Clinical Scenario | Correct Code | Do NOT Use |
|---|---|---|
| NV in patient with no documented DM (BRVO, sickle cell, OIS, radiation, idiopathic) | H35.051 + etiology codes | E11.35x |
| NV in patient with Type 2 DM | E11.351x (proliferative DR, right eye) | H35.051 |
| NV in patient with Type 1 DM | E10.351x (proliferative DR, right eye) | H35.051 |
| NV in patient with prediabetes (R73.09) only — no DM diagnosis | H35.051 (prediabetes ≠ DM) | E11.35x |
| NV in patient with DM + concurrent BRVO | E11.35x for the eye code (DM takes coding priority for retinal NV); H34.831x for the BRVO | Do NOT also use H35.051 for the NV |
| NV bilateral in non-diabetic patient | H35.053 | H35.051 alone |
| NV right eye only | H35.051 | H35.059 (if right eye is documented) |
📌 ICD-9-CM Crosswalk
| ICD-9-CM | Description |
|---|---|
| 362.16 | Retinal neovascularization NOS |
📝 ICD-9-CM 362.16 had no laterality specificity. ICD-10-CM introduced right/left/bilateral/unspecified granularity, significantly improving precision for quality reporting, outcomes analytics, and clinical decision support.
🧑💻 Coder Pearls
- “Unspecified” means etiology — NOT laterality. The right eye is fully specified. The etiology (the systemic cause of the NV) is what’s “unspecified” — meaning non-diabetic but not further attributed to a specific systemic cause. Don’t let the word confuse you or your team.
- The diabetic boundary is absolute. Any documented DM → any retinal NV in that patient → E-code family only. No exceptions. H35.051 is for non-diabetic patients exclusively.
- 67228 PRP is the treatment backbone and has great wRVU. At 3.09 wRVU (non-facility), PRP is one of the higher-value retina procedures. Medical necessity is supported by FA demonstrating NV + NPR → document both clearly.
- FA is explicitly listed in the CMS MAC LCD as a covered service for H35.051. This is strong protection against FA claim denial. Keep the LCD reference in your denial management toolkit.
- OCTA for NV staging is rapidly replacing FA in monitoring. 92137 maps NV network morphology and NPR without dye injection. Cannot be billed same day as 92134 — monitor NCCI edits closely as this is an active audit area in 2026.
- Wide-field imaging is essential for peripheral NV. Standard 30-55° FA or fundus photography can entirely miss peripheral sea-fan NV (sickle cell) or BRVO-related peripheral NVE. Document that wide-field imaging was used to support medical necessity and completeness of the clinical record.
- H35.051 → H35.21- disease progression. When NV matures into full fibrovascular proliferative membranes with traction, consider upgrading the code to H35.21 (non-diabetic proliferative retinopathy, right eye). Query the provider if the record describes membranes and traction.
- Vitreous hemorrhage = H43.13, not H35.051. When NV ruptures and causes a vitreous hemorrhage, sequence H43.13 (right eye) as the principal or primary diagnosis for the acute presentation. H35.051 becomes the secondary etiology code.
- HCC capture is upstream. D57.1 (sickle cell, HCC 47) and I65.21 (carotid stenosis, HCC 108) are the RAF score opportunities in the NV patient — not the H35.051 code itself. Make sure systemic etiologies are clearly documented and coded.
- Anti-VEGF for non-diabetic NV is often off-label. Verify MAC LCD coverage for each agent by indication. When off-label, obtain ABN for Medicare patients (modifier -GA) and document medical necessity thoroughly including failure of or contraindication to PRP.
Sources: ICD-10-CM FY2026 Tabular List, CMS.gov; AAPC Codify H35.051 and H35.05; FindACode H35.051; ECGWaves H35.051 Code Reference; CMS Billing & Coding: Ophthalmic Angiography (FA/ICG) A56774 v22 — H35.051-H35.053 Group 1 Covered Diagnoses; CMS Billing & Coding: Panretinal Scatter Laser Photocoagulation A56550; CMS Billing & Coding: Posterior Segment Imaging A57071 v30; Retinal Physician - Coding Q&A: Laser Photocoagulation Focus, Mar 2017 (updated Oct 2023); Retinal Physician - New Treatments for Sickle Cell Disease, Oct 2025; PMC - Observation of Retinal NV Using OCT Following PRP, Jun 2021; PMC - Laser Therapy for Retinopathy in Sickle Cell Disease, Mar 2023; PubMed - Laser Therapy for Sickle Cell Retinopathy, Oct 2015; CMS Billing & Coding: Ranibizumab and Biosimilars A52451 v75; CMS 2025 Medicare Physician Fee Schedule Final Rule; CMS ICD-10-CM/PCS MS-DRG v42 Definitions Manual